Clinical Trials - March 29, 2022
Atrogi receives regulatory approval from German health authority
Atrogi has received approval from the German authority BfArM to initiate a phase 1 study with their small molecule drug candidate ATR-258 in healthy volunteers and type 2 diabetics. The trial is expected to be completed by year end 2022 with the final report in Q1/2,2023. “Following extensive pre-clinical work, the first study in humans […]
Financing - June 25, 2020
Atrogi receives 1 million EUR Eurostars grant
Atrogi has been selected for a grant from Eurostars, an initiative of the European Commission that promotes research, and the intergovernmental innovation network EUREKA. The application was done in consortium with Stockholm University, Maastricht University, the Latvian Institute of Organic Synthesis and Excellerate Bioscience. The grant awarded is approx. 1 million EUR and will go […]
